Virpax prices $2.25M public offering of common stock and warrants

Virpax Pharmaceuticals, Inc.

Gross proceeds of ~$2.25M from offering of 1,666,667 shares/equivalents plus Series A-1 and A-2 warrants.
Series A-1 warrants exercisable at $1.35/share, expire in 5 years; Series A-2 at $1.35/share, expire in 18 months.
Proceeds to be used for working capital, general corporate purposes, and possibly settling a portion of an obligation.
After closing, 2,741,600 shares of common stock outstanding.
A.G.P./Alliance Global Partners acted as sole placement agent.

item 1.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Virpax Pharmaceuticals, Inc. entered into Purchase Agreement with certain investors (effective 2024-05-14).

Action: entry
Agreement: equity purchase
Counterparty: certain investors
Effective: 2024-05-14

Exact text from the filing

In connection with the Offering, on May 14, 2024, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with certain investors

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Virpax Pharmaceuticals, Inc. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners (effective 2024-05-14).

Action: entry
Agreement: underwriting
Counterparty: A.G.P./Alliance Global Partners
Effective: 2024-05-14

Exact text from the filing

Also, in connection with the Offering, on May 14, 2024, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with A.G.P./Alliance Global Partners (the “Placement Agent”)

View on SEC.gov

290 material agreements filed in the last 30 days. Browse all material agreements →

Source: SEC EDGAR

accession 0001213900-24-044747

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.